<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>p53 inactivation is often observed in Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) cells, because of either mutations in p53 gene or an overexpression of the p53-negative regulator MDM2 </plain></SENT>
<SENT sid="1" pm="."><plain>Epstein-Barr virus (EBV) is present in virtually 100% of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cases occurring in endemic areas, but in only 10-20% of <z:hpo ids='HP_0003745'>sporadic</z:hpo> cases </plain></SENT>
<SENT sid="2" pm="."><plain>In EBV(-) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells, reactivation of p53, induced by reducing MDM2 protein level, led to <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="3" pm="."><plain>We show here that <z:chebi fb="0" ids="46742">nutlin-3</z:chebi>, a potent <z:chebi fb="68" ids="48706">antagonist</z:chebi> of MDM2, activates the p53 pathway in <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell lines harboring <z:mp ids='MP_0002169'>wild-type</z:mp> p53, regardless of EBV status </plain></SENT>
<SENT sid="4" pm="."><plain>However, <z:chebi fb="0" ids="46742">nutlin-3</z:chebi> strongly induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in EBV(-) or latency I EBV(+) cells, whereas latency III EBV(+) cells were much more resistant </plain></SENT>
<SENT sid="5" pm="."><plain>Prior treatment with sublethal doses of <z:chebi fb="0" ids="46742">nutlin-3</z:chebi> sensitizes EBV(-) or latency I EBV(+) cells to <z:mpath ids='MPATH_3'>apoptosis</z:mpath> induced by <z:chebi fb="0" ids="4911">etoposide</z:chebi> or melphalan, but protects latency III EBV(+) cells </plain></SENT>
<SENT sid="6" pm="."><plain>p21(WAF1) which is overexpressed in the latter, is involved in this protective effect, as siRNA-mediated inhibition of p21(WAF1) restores sensitivity to <z:chebi fb="0" ids="4911">etoposide</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="46742">Nutlin-3</z:chebi> protects latency III <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells by inducing a p21(WAF1)-mediated G1 arrest </plain></SENT>
<SENT sid="8" pm="."><plain>Most <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> patients with <z:mp ids='MP_0002169'>wild-type</z:mp> p53 <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> could therefore benefit from treatment with <z:chebi fb="0" ids="46742">nutlin-3</z:chebi>, after a careful determination of the latency pattern of EBV in infected patients </plain></SENT>
</text></document>